A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD3974 After Single and Multiple Ascending Dosing to Healthy Participants
Latest Information Update: 26 Dec 2025
At a glance
- Drugs AZD 3974 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
Most Recent Events
- 25 Dec 2025 New trial record
- 23 Dec 2025 Status changed from not yet recruiting to recruiting.